Last reviewed · How we verify

NCT06806202

Warm Versus Conventional 2% Lignocaine for IANB Efficacy

Recruiting now Phase 2 Last updated 3 February 2025
What this trial tests

Phase 2 trial testing conventional 2% lignocaine at room temperature in Success of Inferior Alveolar Nerve Block in 200 participants. Currently enrolling.

Timeline
15 December 2024
Primary endpoint
15 March 2025
15 March 2025

Quick facts

Lead sponsorArmed Forces Institute of Dentistry, Pakistan
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment200
Start date15 December 2024
Primary completion15 March 2025
Estimated completion15 March 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Armed Forces Institute of Dentistry, Pakistan

Who can join

Adults 18 to 50, any sex, with Success of Inferior Alveolar Nerve Block or Inferior Alveolar Nerve Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study compares the anesthetic efficacy of warm versus conventional 2% lignocaine for inferior alveolar nerve block in mandibular molars, evaluating success rates and onset time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Armed Forces Institute of Dentistry, Pakistan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06806202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing